KLRK1 and neoplasm: First, while our findings demonstrate the efficacy of NKG2D CAR T cells across three distinct preclinical models, independent repetition of the in vivo studies should be conducted to further validate the robustness of these results, which is vital for drawing rigorous conclusions; and long-term observation or rechallenge with live tumor cells are needed for further study to highlight OS difference between therapy of NKG2D CAR T with or without radiotherapy.